Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

513.12
-7.8800-1.51%
Post-market: 513.310.1900+0.04%19:30 EDT
Volume:415.57K
Turnover:215.18M
Market Cap:22.01B
PE:18.36
High:528.02
Open:523.23
Low:512.29
Close:521.00
52wk High:609.35
52wk Low:302.19
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.96
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.44
PE(LYR):18.42

Loading ...

Vanda Pharmaceuticals Q2 Loss Widens on Lower Sales, Higher Costs

Reuters
·
Aug 06

United Therapeutics Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

United Therapeutics Q2 Net Income Rises, Revenue Falls

MT Newswires Live
·
Aug 05

United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips

TradingKey
·
Aug 05

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates

Stock Track
·
Aug 05

Earnings Flash (UTHR) United Therapeutics Posts Q2 EPS $7.27, vs. FactSet Est of $6.86

MT Newswires Live
·
Aug 05

United Therapeutics Q2 Revenue USD 783.3 Million Vs. IBES Estimate USD 805.6 Million

Reuters
·
Aug 05

United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M Estimate

Benzinga Earnings
·
Aug 05

United Therapeutics Q2 EPS USD 7.27

THOMSON REUTERS
·
Aug 05

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05

United Therapeutics Chairperson, CEO Martine Rothblatt Reports Disposal of 9,500 Common Shares for $4.9 Million

Reuters
·
Aug 05

United Therapeutics CEO Martine Rothblatt Disposes of Common Shares Worth $4.96 Million

Reuters
·
Jul 30

United Therapeutics Says FDA Reviews Ralinepag NDA for Pulmonary Arterial Hypertension

Reuters
·
Jul 29

United Therapeutics Corp - Advance Outcomes Phase 3 Study of Ralinepag in Pah Meets Primary and Secondary Endpoints

THOMSON REUTERS
·
Jul 29

Earning Preview: United Therapeutics Q2 revenue is expected to increase by 0.17%, and institutional views are bullish

Earnings Agent
·
Jul 29

United Therapeutics CEO Martine Rothblatt Reports Sale of 9,500 Common Shares Worth $5.04 Million

Reuters
·
Jul 27

Did a High-Profile Board Addition and ESOP Moves Just Shift United Therapeutics' (UTHR) Investment Narrative?

Simply Wall St.
·
Jul 24

United Therapeutics Director Victor J. Dzau Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

United Therapeutics CEO Martine A. Rothblatt Disposes of 8,500 Common Shares Worth $4.53 Million

Reuters
·
Jul 24